📊 URGN Key Takeaways
Is UroGen Pharma Ltd. (URGN) a Good Investment?
UroGen is a revenue-generating biotech with strong 88.7% gross margins and 21.4% revenue growth, but faces severe financial distress. Negative stockholders' equity of -$105.5M combined with -$162.4M annual operating cash burn leaves the company technically insolvent with less than 9 months of runway at current burn rates. Without near-term profitability or capital infusion, significant shareholder dilution or restructuring is highly likely.
Why Buy UroGen Pharma Ltd. Stock? URGN Key Strengths
- Strong gross margins of 88.7% demonstrate products have viable economics
- Revenue growing 21.4% YoY indicates commercial traction and market acceptance
- Adequate near-term liquidity with $110.7M cash and 4.01x current ratio
URGN Stock Risks: UroGen Pharma Ltd. Investment Risks
- Negative stockholders' equity of -$105.5M indicates technical insolvency
- Operating cash burn of -$162.4M limits runway to approximately 8 months without capital raise
- Net losses of -$153.5M and operating margin of -113.7% despite revenue growth shows expenses are scaling faster than sales
- Long-term debt of $125.0M alongside negative equity creates refinancing pressure
- Path to profitability unclear with no evidence operating leverage is improving
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF
- Stockholders' equity recovery timeline
- Cash balance and months of runway remaining
- Revenue growth sustainability and gross margin trajectory
- Operating expense reductions and achievement of operating leverage
UroGen Pharma Ltd. (URGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.01x current ratio provides a solid financial cushion.
URGN Profit Margin, ROE & Profitability Analysis
URGN vs Healthcare Sector: How UroGen Pharma Ltd. Compares
How UroGen Pharma Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is UroGen Pharma Ltd. Stock Overvalued? URGN Valuation Analysis 2026
Based on fundamental analysis, UroGen Pharma Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
UroGen Pharma Ltd. Balance Sheet: URGN Debt, Cash & Liquidity
URGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: UroGen Pharma Ltd.'s revenue has grown significantly by 129% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.96 indicates the company is currently unprofitable.
URGN Revenue Growth, EPS Growth & YoY Performance
URGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $25.2M | -$23.7M | $-0.51 |
| Q2 2025 | $21.8M | -$33.4M | $-0.82 |
| Q1 2025 | $18.8M | -$32.3M | $-0.87 |
| Q3 2024 | $20.9M | -$21.9M | $-0.55 |
| Q2 2024 | $21.1M | -$24.1M | $-0.91 |
| Q1 2024 | $17.2M | -$30.2M | $-0.97 |
| Q3 2023 | $16.1M | -$21.9M | $-0.68 |
| Q2 2023 | $16.6M | -$24.1M | $-1.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
UroGen Pharma Ltd. Dividends, Buybacks & Capital Allocation
URGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for UroGen Pharma Ltd. (CIK: 0001668243)
📋 Recent SEC Filings
❓ Frequently Asked Questions about URGN
What is the AI rating for URGN?
UroGen Pharma Ltd. (URGN) has an AI rating of STRONG SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are URGN's key strengths?
Claude: Strong gross margins of 88.7% demonstrate products have viable economics. Revenue growing 21.4% YoY indicates commercial traction and market acceptance.
What are the risks of investing in URGN?
Claude: Negative stockholders' equity of -$105.5M indicates technical insolvency. Operating cash burn of -$162.4M limits runway to approximately 8 months without capital raise.
What is URGN's revenue and growth?
UroGen Pharma Ltd. reported revenue of $109.8M.
Does URGN pay dividends?
UroGen Pharma Ltd. does not currently pay dividends.
Where can I find URGN SEC filings?
Official SEC filings for UroGen Pharma Ltd. (CIK: 0001668243) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is URGN's EPS?
UroGen Pharma Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is URGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, UroGen Pharma Ltd. has a STRONG SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is URGN stock overvalued or undervalued?
Valuation metrics for URGN: ROE of N/A (sector avg: 15%), net margin of -139.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy URGN stock in 2026?
Our dual AI analysis gives UroGen Pharma Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is URGN's free cash flow?
UroGen Pharma Ltd.'s operating cash flow is $-162.4M, with capital expenditures of $289.0K. FCF margin is -148.2%.
How does URGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -139.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.01 (avg: 2).